Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure von LUO, Feng R, ZHENG YANG, WEN, Mei-Li, KRAMER, Robert, BLACKWOOD-CHIRCHIR, Anne, LEE, Francis Y, CAMUSO, Amy, SMYKLA, Richard, MCGLINCHEY, Kelly, FAGER, Krista, FLEFLEH, Christine, CASTANEDA, Stephen, INIGO, Ivan, KAN, David

Volltext

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression level... von Wild, Robert, Fager, Krista, Flefleh, Christine, Kan, David, Inigo, Ivan, Castaneda, Stephen, Luo, Feng Roger, Camuso, Amy, McGlinchey, Kelly, Rose, William C

Volltext

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model von LUO, Feng R, ZHENG YANG, WONG, Tai W, KRAMER, Robert A, WILD, Robert, LEE, Francis Y, HUIJIN DONG, CAMUSO, Amy, MCGLINCHEY, Kelly, FAGER, Krista, FLEFLEH, Christine, KAN, David, INIGO, Ivan, CASTANEDA, Stephen

Volltext

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor von Luo, Feng (Roger), Barrett, Yu Chen, Yang, Zheng, Camuso, Amy, McGlinchey, Kelly, Wen, Mei-Li, Smykla, Richard, Fager, Krista, Wild, Robert, Palme, Holly, Galbraith, Susan, Blackwood-Chirchir, Anne, Lee, Francis Y.

Volltext

Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors von Lombardo, Louis J., Camuso, Amy, Clark, John, Fager, Krista, Gullo-Brown, Johnni, Hunt, John T., Inigo, Ivan, Kan, David, Koplowitz, Barry, Lee, Francis, McGlinchey, Kelly, Qian, Ligang, Ricca, Carolyn, Rovnyak, George, Traeger, Sarah, Tokarski, John, Williams, David K., Wu, Laurence I., Zhao, Yufen, Manne, Veeraswamy, Bhide, Rajeev S.

Volltext

Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML) von Lee, Francis Y., Wen, Mei-Li, Bhide, Rajeev, Camuso, Amy, Castenada, Stephen, Fager, Krista, Flefleh, Christine, Inigo, Ivan, Kan, David, Luo, Roger, McGlinchey, Kelly, Smykla, Richard, Wild, Robert, Borzilleri, Robert, Lombardo, Louis

Volltext

Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique... von Lee, Francis Y., Wen, Mei-Li, Camuso, Amy, Castenada, Stephen, Fager, Krista, Flefleh, Christine, Inigo, Ivan, Luo, Roger, Kan, David, Manne, Veeraswamy, McGlinchey, Kelly, Smykla, Richard, Weinmann, Roberto, Kramer, Robert

Volltext

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth von Wild, Robert, Castaneda, Stephen, Flefleh, Christine, Fager, Krista, Inigo, Ivan, Kan, David, Smykla, Richard, Camuso, Amy, McGlinchey, Kelly, Wen, Mei-Li, Luo, Feng Roger, Borzilleri, Robert, Lombardo, Louis, Kramer, Robert, Lee, Francis Y.

Volltext

Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825 von Luo, Feng Roger, Yang, Zheng, Camuso, Amy, Smykla, Richard, Castenada, Stephen, Flefleh, Christine, Fager, Krista, Inigo, Ivan, Kan, David, McGlinchey, Kelly, Wen, Mei-Li, Wild, Robert, Borzilleri, Robert, Lombardo, Louis, Kramer, Robert, Lee, Francis Y.

Volltext